|
AU594014B2
(en)
|
1984-03-21 |
1990-03-01 |
Research Corporation Technologies, Inc. |
Recombinant DNA molecules
|
|
CA1282721C
(en)
|
1984-06-04 |
1991-04-09 |
Bernard Roizman |
Herpes simplex virus as a vector
|
|
US5288641A
(en)
|
1984-06-04 |
1994-02-22 |
Arch Development Corporation |
Herpes Simplex virus as a vector
|
|
DE3584341D1
(de)
|
1984-08-24 |
1991-11-14 |
Upjohn Co |
Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US5698531A
(en)
|
1989-03-31 |
1997-12-16 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US5328688A
(en)
|
1990-09-10 |
1994-07-12 |
Arch Development Corporation |
Recombinant herpes simplex viruses vaccines and methods
|
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
|
US6040169A
(en)
|
1991-01-31 |
2000-03-21 |
Medical Research Council |
Herpes simplex virus-1 deletion variants and vaccines thereof
|
|
ES2183811T3
(es)
|
1992-03-31 |
2003-04-01 |
Arch Dev Corp |
Tratamiento de enfermedades tumorigenas con un hsv modificado.
|
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
JPH11513390A
(ja)
|
1995-10-06 |
1999-11-16 |
アーチ デベロップメント コーポレイション |
細胞殺傷のウイルス増強のための方法および組成物
|
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
|
GB9700411D0
(en)
*
|
1997-01-10 |
1997-02-26 |
Univ London |
Eukaryotic gene expression cassette and uses thereof
|
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
CA2720361A1
(en)
|
1999-11-12 |
2001-05-25 |
Oncolytics Biotech, Inc. |
Viruses for the treatment of cellular proliferative disorders
|
|
ATE312189T1
(de)
|
2000-01-21 |
2005-12-15 |
Biovex Ltd |
Virusstämme für die onkolytische behandlung von krebs
|
|
ES2366608T3
(es)
|
2001-03-27 |
2011-10-21 |
The General Hospital Corporation |
Vectores víricos y su uso en métodos terapéuticos.
|
|
GB0317511D0
(en)
|
2003-07-25 |
2003-08-27 |
Biovex Ltd |
Viral vectors
|
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
CA2586844A1
(en)
|
2004-11-04 |
2006-05-11 |
Pfizer Products Inc. |
Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
|
|
LT2620450T
(lt)
|
2005-03-08 |
2019-02-11 |
Pfizer Products Inc. |
Anti-ctla-4 antikūnų kompozicijos
|
|
JP5284780B2
(ja)
|
2005-06-23 |
2013-09-11 |
ザ ユニバーシティ オブ ヒューストン |
癌の治療のための単純ヘルペスウイルス２型変異体の使用
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
US9868961B2
(en)
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
|
KR101361416B1
(ko)
|
2008-10-08 |
2014-02-21 |
인트렉손 코포레이션 |
다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
AU2010321773A1
(en)
|
2009-11-20 |
2012-06-14 |
Infinity Pharmaceuticals, Inc. |
Methods and compositions for treating hedgehog-associated cancers
|
|
WO2011119925A2
(en)
|
2010-03-25 |
2011-09-29 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthetic herpes simplex viruses for treatment of cancers
|
|
WO2011118866A1
(ko)
|
2010-03-26 |
2011-09-29 |
연세대학교 산학협력단 |
네트워크를 통한 심사요청 방법
|
|
BR112013006699A2
(pt)
|
2010-09-24 |
2016-06-14 |
Oncos Therapeutics Oy |
vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
|
|
FI20115914A7
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
DK2806883T3
(da)
|
2012-01-25 |
2019-07-22 |
Dnatrix Inc |
Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
|
|
KR20170039774A
(ko)
*
|
2012-07-30 |
2017-04-11 |
알렉스 와 힌 영 |
종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
|
|
FI3381942T4
(fi)
|
2012-08-30 |
2025-12-16 |
Amgen Inc |
Menetelmä melanooman hoitamiseksi herpes simplex -virusta ja immuuniaktivaation vapauttajaa käyttäen
|
|
US9789182B2
(en)
|
2012-10-23 |
2017-10-17 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
KR102222157B1
(ko)
|
2013-03-14 |
2021-03-03 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
뉴캐슬병 바이러스 및 이의 용도
|
|
KR102310692B1
(ko)
|
2013-09-03 |
2021-10-12 |
메디뮨 리미티드 |
약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
|
|
SG11201602887QA
(en)
|
2013-10-25 |
2016-05-30 |
Psioxus Therapeutics Ltd |
Oncolytic adenoviruses armed with heterologous genes
|
|
KR102490462B1
(ko)
|
2013-10-28 |
2023-01-19 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
종양분해성 hsv 벡터
|
|
KR20160137946A
(ko)
|
2013-11-22 |
2016-12-02 |
디엔에이트릭스, 인코포레이티드 |
면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
|
|
US10933106B2
(en)
|
2014-02-25 |
2021-03-02 |
Deutsches Krebsforschungszentrum |
RNA viruses for immunovirotherapy
|
|
MA39818A
(fr)
|
2014-03-30 |
2017-02-08 |
Benevir Biopharm Inc |
Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
|
|
US10765710B2
(en)
|
2014-07-16 |
2020-09-08 |
Institut Gustave-Roussy |
Combination of oncolytic virus with immune checkpoint modulators
|
|
EP3552615B8
(en)
|
2014-07-16 |
2022-03-02 |
Transgene |
Oncolytic virus for expression of immune checkpoint modulators
|
|
US20160040186A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Xiaoyun Liu |
Dna construct and method for transgene expression
|
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
WO2016118865A1
(en)
|
2015-01-23 |
2016-07-28 |
Dreamwell, Ltd. |
Automated mattress manufacturing process and apparatus
|
|
CN104987421A
(zh)
*
|
2015-05-13 |
2015-10-21 |
北京比洋生物技术有限公司 |
抗ctla-4和pd-1的双重可变结构域免疫球蛋白
|
|
WO2017118866A1
(en)
|
2016-01-08 |
2017-07-13 |
Replimune Limited |
Engineered virus
|
|
RU2751236C2
(ru)
*
|
2016-04-22 |
2021-07-12 |
Иммвира Ко., Лимитед |
КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EP3810191A1
(en)
*
|
2018-06-21 |
2021-04-28 |
Replimune Limited |
Treatment using oncolytic virus
|